comparemela.com

Latest Breaking News On - Anne hennecke - Page 16 : comparemela.com

Abivax Reports Two-Year Efficacy and Safety Data of Obefazimod Phase 2b Maintenance Trial in Ulcerative Colitis

The analysis demonstrates clinical remission in 52.5% (n=114) of 217 moderate to severe ulcerative colitis (UC) patients (intent-to-treat population, ITT) after two years (96 weeks) of once-daily oral

EQS-News: Abivax reports two-year efficacy and safety data of obefazimod phase 2b maintenance trial in ulcerative colitis

vimarsana © 2020. All Rights Reserved.